首页> 外文会议>International Symposium on Micro-NanoMechatronics and Human Science >Interleukin-21 as an Effective Suppressant for IgE-mediated Allergic Hypersensitivity Reactions
【24h】

Interleukin-21 as an Effective Suppressant for IgE-mediated Allergic Hypersensitivity Reactions

机译:白细胞介素-21作为IgE介导的过敏性超敏反应的有效抑制剂

获取原文

摘要

IgE plays essential roles in the pathogenesis of many allergic disorders including bronchial asthma, allergic rhinitis, atopic dermatitis, and anaphylaxis. If IgE production can be effectively and safely controlled in patients, such procedures may alleviate allergic symptoms, leading to novel therapeutic and prophylactic interventions of allergic diseases. Interleukin-21 (IL-21) is a cytokine produced by activated T cells. It exerts pleiotropic immunomodulatory functions through acting on various immune cells including T, B, and NK cells. To analyze influence of exogenous IL-21 in vivo, we inserted an expression unit of IL-21 cDNA into an Epstein-Barr virus (EBV)-based artificial chromosome, so that extremely powerful and long-lasting expression of the cytokine can be achieved in vivo in the liver. Peanut anaphylactic mice were established by repetitive immunization with the crude peanut extract (CPE) as an allergen, and they received intravenous administration of the DNA construct through the tail vein under high pressure. As the results, anaphylactic symptoms were completely abrogated by the IL-21 gene treatment, in striking contrast to untreated allergic mice that showed extremely severe systemic disturbance. Serum level of IgE was also drastically suppressed by IL-21 gene treatment. Then we used recombinant IL-21 (rIL-21) to treat anaphylactic as well as allergic rhinitis mice, which also showed significant remission of the diseases. As the mechanisms of the IgE regulation, we found that expression of germ line Cε transcript was suppressed in B cells that were treated with rIL-21 in vitro or in vivo, suggesting that IL-21 effectively suppressed the class switch recombination (CSR) to IgE. The present findings strongly suggest that IL-21 can be used as a novel molecular medicine to control allergy. It was also shown that the EBV-based artificial chromosome provides a useful means to analyze bioactivity in vivo of various genes in mammals, providing a platform to investigate functions of genes as well as to discover promising molecules for therapeutic molecular targeting to treat various disorders.
机译:IgE在许多过敏性疾病的发病机制中起重要作用,包括支气管哮喘,过敏性鼻炎,特内皮炎和过敏反应。如果可以在患者有效和安全地控制IgE的产生,这种程序可能会缓解过敏症状,导致过敏性疾病的新治疗和预防性干预措施。白细胞介素-21(IL-21)是由活化的T细胞产生的细胞因子。它通过作用于包括T,B和NK细胞的各种免疫细胞来施加脂肪术免疫调节功能。为了分析外源IL-21在体内的影响,我们将IL-21 cDNA的表达单位插入到综合的人工染色体中,从而可以实现细胞因子的极其强大和持久的表达在肝脏体内。通过用粗花生提取物(CPE)作为过敏原的重复免疫建立了花生过敏小鼠,并且它们在高压下通过尾静脉接受静脉内施用DNA构建体。结果,通过IL-21基因治疗完全消除过敏性症状,与未经处理过的过敏小鼠显着造影,表现出极其严重的全身扰动。 IL-21基因处理也急剧抑制血清IgE。然后我们使用重组IL-21(RIL-21)治疗过敏性和过敏性鼻炎小鼠,这也表现出疾病的显着缓解。作为IGE调节的机制,我们发现在体外或体内用RIL-21处理的B细胞中抑制了生殖系Cε转录物的表达,表明IL-21有效地抑制了阶级开关重组(CSR) IgE。本研究结果强烈表明IL-21可用作对控制过敏的新型分子药物。还表明基于EBV的人工染色体提供了一种有用的手段,用于分析哺乳动物中各种基因的体内生物活性,提供了调查基因函数的平台,以及发现治疗分子靶向治疗各种疾病的有希望的分子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号